linjc16/ctgov huggingface dataset:
Early Mobilization After Arthroplasty

Study Overview
=================
Brief Summary
-----------------
Aims and Objectives: This study was conducted in order to determine the factors that affected the early mobilization after surgery of patients who had undergone knee and hip arthroplasty. Background: Early mobilization in knee and hip arthroplasty is still not at the desired level, and it is among the most frequently overlooked nursing practices. Desing: This study is descriptive and cross-sectional. STROBE checlist was used to compile the study's report. Methods: The universe of the study consisted of a total of 80 patients who were hospitalized between 07 November 2017 and 21 September 2018 in the Orthopedics and Traumatology Clinic of a State Hospital to undergo knee or hip arthroplasty, and who met the inclusion criteria. The sample of the study consisted of 60 patients who were in the universe of the study, who met the inclusion criteria and who voluntarily agreed to participate in the study.

Official Title
-----------------
Determination of Factors Affecting Early Mobilization of Patients Who Have Undergone Knee and Hip Arthroplasty

Conditions
-----------------
Mobility

Intervention / Treatment
-----------------
* Other: early mobilization


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Admitted to the Orthopedics and Traumatology Clinic for the first time to undergo knee or hip arthroplasty, Communicating, No hearing or speech impairment, 18 years and older patients. Exclusion Criteria: Undergoing revision surgery, Having a history of lower extremity orthopedic intervention that may prevent mobilization, Having neurological and medical problems that may cause locomotor disability, Uncontrollable heart and lung diseases, Having a history of neurological disease (Alzheimer's, dementia, etc.), Patients with gout, metabolic diseases or septic arthritis.

Ages Eligible for Study
-----------------
Minimum Age: 48 Years
Maximum Age: 94 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: early mobilization|early mobilization was defined, on the basis of the ERAS protocol, as mobilization of a few steps or a few meters from the bed within the first 24 hours after surgery with another person's support/control and/or a walking aid.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The status of successful mobilization within 24 hours after surgery | Early mobilization was defined, on the basis of the ERAS protocol, as mobilization of a few steps or a few meters from the bed within the first 24 hours after surgery with another person's support/control and/or a walking aid. | 24 Hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Early Mobilization, Enhanced Recovery After Surgery (ERAS), Arthroplasty, Nursing
4G/5G Polymorphism of Plasminogen Activator Inhibitor-1 Gene and Disseminated Intravascular Coagulation in Severe Sepsis and Septic Shock

Study Overview
=================
Brief Summary
-----------------
Data on 4G/5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene are limited in Asian patients with sepsis. Therefore, the investigators aim to prospectively investigate the incidence of 4G/5G polymorphism and its relationship with disseminated intravascluar coagulatin in patients with severe sepsis and septic shock.

Official Title
-----------------
Incidence and Prognosis of Disseminated Intravscular Coagulation in Patients Severe Sepsis and Septic Shock; Association With 4G/5G Polymorphism of PAI-1 Gene

Conditions
-----------------
Severe Sepsis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patinents aged > 18 years, Patients satisfying the criteria by 2008 Surviving Sepsis Campagin, Patients who are determined as having a sepsis within 24 hours of ICU stay Exclusion Criteria: Do-not-resuscitate, cardiopulmonary resuscitation, ICU stay < 1 day, Refusal to participate in the study, Hematologic malignancy or liver cirrhosis (Child C), Congenital abnormality in coagulation system, Transfer from other ICUs or hospitals

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
polymorphism,, plasminogen activator inhibitor,, disseminated intravascular coagulation,
Safety and Effectiveness Evaluation of COBRA PzF Coronary Stent System: A Post Marketing Observational Registry

Study Overview
=================
Brief Summary
-----------------
A multi-center, prospective, consecutive enrolled, observational registry. The population being studied includes all patients undergoing treatment of de novo lesions in native coronary vessels, saphenous vein graft and/or arterial bypass conduits with the COBRA PzF coronary stent system. The registry will primarily assess the rate of MACE (cardiac death, myocardial infarction and clinically driven target lesion revascularization.

Official Title
-----------------
Safety And Effectiveness Evaluation Of COBRA PzF™ Coronary Stent System: A French Observational Postmarketing Registry

Conditions
-----------------
Stable Angina, Unstable Angina, ACS - Acute Coronary Syndrome, STEMI, NSTEMI - Non-ST Segment Elevation MI, Myocardial Infarction

Intervention / Treatment
-----------------
* Device: COBRA PzF Coronary Stent System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient has given oral consent to participate in the registry Patient is implanted with a COBRA PzF stent Target lesion(s) is/are de novo Exclusion Criteria: Pregnancy Age <18 years Refusal or inability to give oral consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: COBRA PzF Coronary Stent System|COBRA PzF Coronary Stent System|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MACE | Composite clinical endpoint of cardiac death, myocardial infarction, and clinically driven target lesion revascularization | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stent thrombosis | Stent thrombosis (according to ARC definition) | 12 months | 
| TVR and TLR | Target vessel and lesion revascularization | 12 months | 
| DAPT | Mean length of dual antiplatelet therapy | 12 months |
A Study to Evaluate Inhibition of Ovulation of Two Oral Estrogen/Progestogen Regimens in Healthy, Young Females Over a Period of 3 Treatment Cycles

Study Overview
=================
Brief Summary
-----------------
Investigation of a new pill containing an estrogen and a progestin in order to monitor the inhibition of the ovulation in young healthy females over 3 treatment cycles

Official Title
-----------------
A Double-blind, Randomized, Uncontrolled Study to Evaluate Inhibition of Ovulation of Two Oral Estradiol / Drospirenone Regimens in Healthy Young Female Volunteers Over a Period of 3 Treatment Cycles

Conditions
-----------------
Contraception

Intervention / Treatment
-----------------
* Drug: BAY86-4891 (Estradiol / Drospirenone)
* Drug: BAY86-4891 (Estradiol / Drospirenone)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy female volunteers, Age 18 - 35 years Exclusion Criteria: Contraindications for use of a combined (estrogen/progestogen) contraceptive (e.g. history of venous/arterial thromboembolic disease) Regular intake of medication Clinically relevant findings (ECG, blood pressure, physical, gynecological examination, laboratory examination) Anovulatory pre-treatment cycle

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm 1<br> | Drug: BAY86-4891 (Estradiol / Drospirenone)<br>* Monophasic regimen containing estrogen and progestin 1 pre-treatment cycle, 3 treatment cycles<br>|
| Experimental: Arm 2<br> | Drug: BAY86-4891 (Estradiol / Drospirenone)<br>* Triphasic regimen containing estrogen and progestin 1 pre-treatment cycle, 3 treatment cycles<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary efficacy variable will be the proportion of volunteers with ovulation in at least one of the treatment cycles 2 and 3, based on the binary variable ovulation (i.e. Hoogland score 6) with the levels yes and no |  | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of ovarian activity in treatment cycles 2 and 3 |  | 12 months | 
| Course of gonadotropins (FSH, LH) |  | 12 months | 
| Endometrial growth |  | 12 months | 
| Pharmacokinetics of estrogen and progestin in treatment cycle 3 |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Contraception
Primary Graft Dysfunction Score in Lung Transplantation

Study Overview
=================
Brief Summary
-----------------
The validity of several functional parameters, which could be included in a new PGD scoring system, will be tested in a prospective pilot study of 80 consecutive bilateral lung transplant recipients in high volume lung transplant centers. Functional parameters will be collected at different time points within the first 72hrs after lung transplantation and their accuracy in predicting clinical outcome as well as their correlation with lung water content (measured by PiCCO) will be tested. Insights will serve to generate a hypothesis (a novel PGD score), which can then be tested in future prospective trials.

Official Title
-----------------
Finding New Criteria for a Revised Primary Graft Dysfunction Score in Lung Transplantation - a Pilot Study

Conditions
-----------------
Lung Transplant; Complications

Intervention / Treatment
-----------------
* Device: PiCCO Catheter


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Double lung transplantation for primary pulmonary hypertension (PPH), Fibrosis, cystic fibrosis (CF), Emphysema No restrictions regarding donor lungs (marginal donors, EVLP possible) No restrictions regarding size reduction (anatomic wedge resections, three lobar, lobar transplantations) Exclusion Criteria: Single-lung transplantation Heart-lung transplantation Re-transplantation Patients with bridge-to-transplantation with a mechanical assist device (extra-corporal membrane oxygenation (v/v, v/a), PA/LA Novalung, ILAactive, ILA) Clinical situations leading to inaccurate PiCCO measurements e.g. intracardiac shunts, significant tricuspid regurgitation, cooling No access to the femoral artery possible Severe postoperative hemorrhage, which leads to hematothorax and makes revision surgery necessary

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: PiCCO Catheter|The PiCCO Catheter is an investigational device intended to measure lung water content in individuals requiring advanced haemodynamic monitoring. The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary graft dysfunction |  | 72 hours after transplantation |
Long-Term Outcomes in the Treatment of Infantile and Acquired Esotropia With Botulinum Toxin

Study Overview
=================
Brief Summary
-----------------
To investigate long-term treatment outcomes of patients receiving botulinum toxin A therapy for infantile and acquired esotropia.

Detailed Description
-----------------
Participants: 164 patients with infantile esotropia and 89 patients with acquired esotropia. Methods: Patients were injected with botulinum toxin into two medial rectus muscles and followed from 1992 to 2005. Patients were evaluated at 1 week, 2, 6 and 12 months, and then yearly post-injection. Main Outcome Measures: Degree of motor alignment, recurrence rate, incidence of stereopsis, and dissociated vertical deviation along with complications.

Official Title
-----------------
Long-Term Outcomes in the Treatment of Infantile and Acquired Esotropia With Botulinum Toxin

Conditions
-----------------
Esotropia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: infantile esotropia and acquired esotropia Exclusion Criteria: exotropia, high AC/A ratio accommodative esotropia, patients with neurological deficit including cerebral palsy, Down syndrome and mental retardation, and ocular anomalies including retinopathy of prematurity. Patients lost to follow-up at 6 months or less after the last injection were also excluded.

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 5 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>infantile esotropia | |
| 2<br>acquired esotropia | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Degree of motor alignment, recurrence rate, incidence of stereopsis, and dissociated vertical deviation along with complications. |  | Before treatment, weekly after the treatment, and monthly after motor alignment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
botulinum, esotropia
Different Metabolic Effects of Statins

Study Overview
=================
Brief Summary
-----------------
The investigators hypothesize that pravastatin and rosuvastatin may have different metabolic effects in hypercholesterolemic patients.

Conditions
-----------------
Hypercholesterolemia

Intervention / Treatment
-----------------
* Drug: pravastatin, rosuvastatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Low-density lipoprotein cholesterol levels>130 Exclusion Criteria: Overt liver disease Chronic renal failure Hypothyroidism Myopathy Uncontrolled diabetes Severe hypertension

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| pravastatin<br> | Drug: pravastatin, rosuvastatin<br> <br> |
| rosuvastatin<br> | Drug: pravastatin, rosuvastatin<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Statins, Insulin resistance
Radiomics Analysis of Focal Liver Lesions Based on Contrast-Enhanced Ultrasound Imaging

Study Overview
=================
Brief Summary
-----------------
Contrast-enhanced ultrasound (CEUS) substantially improves the potential of ultrasound (US) for the identification and characterization of focal liver lesions (FLLs). Compared to contrasted-enhanced MRI and CT, it has some unique advantages, such as the absence of ionizing radiation, and easy operability and repeatability. However, the efficacy of CEUS in diagnosing liver lesions is challenged by several factors including being highly dependent on doctor's experience, low signal-to-noise ratio, and low interobserver agreement. Therefore, it is a beneficial attempt to construct an intelligent CEUS diagnosis system using digital information technology. This study aims to collect standard data of CEUS cines recordings and develop deep learning model for accurate segmentation, detection and classification of liver lesions.

Official Title
-----------------
Research on Key Techniques for Intelligent Diagnosis and Ablation Decision-making of Liver Cancer and Evolution by Contrast-enhanced Ultrasound

Conditions
-----------------
Focal Liver Lesions, Contrast-enhanced Ultrasound

Intervention / Treatment
-----------------
* Diagnostic Test: diagnosis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with a solid liver tumor visible during routine ultrasound and received CEUS. disease history and standard of reference of the lesions can be acquired Exclusion Criteria: hypersensitivity for ultrasound contrast media pregnant or lactating patients previously treated lesions or local relapse from previously treated lesions diffuse tumors
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: diagnosis|there is no intervention diagnosis or treatment for patients|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUC value | Area under the receiver operating characteristic (ROC) curve (AUC） | through study completion, an average of 7 year | 
| specificity | diagnosis specificity of intelligent CEUS analysis | through study completion, an average of 7 year | 
| sensitivity | diagnosis sensitivity of intelligent ultrasound analysis | through study completion, an average of 3 year |
By Developing a Radiomics Model to Predict the Prognosis of Patients With Hepatocellular Carcinoma After Microwave Ablation

Study Overview
=================
Brief Summary
-----------------
Developing a radiomics model to predict the prognosis of patients with hepatocellular carcinoma after microwave ablation to provide advice for their treatment.

Official Title
-----------------
By Developing a Radiomics Model to Predict the Prognosis of Patients With Hepatocellular Carcinoma After Microwave Ablation

Conditions
-----------------
Hepatocellular Carcinoma

Intervention / Treatment
-----------------
* Procedure: Microwave abaltion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with primary hepatocellular carcinoma in the department of interventional ultrasound, PLA general hospital, who accept MWA therapy for HCC Inclusion criteria: Primary hepatocellular No other treatments ware performed before microwave ablation Patient has been clinically diagnosed with HCC definitely, and have a definite operational indication No extrahepatic manifestations and no evidence of vessel invasion and bile duct thrombi Exclusion Criteria: Exclusion criteria: Non-primary hepatocellular carcinoma or hepatic metastases Accept other treatment before microwave ablation Extrahepatic metastasis, vessel invasion or bile duct thrombi

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Good prognosis<br> | Procedure: Microwave abaltion<br>* Use microwave ablation to treat hepatocellular carcinoma<br>|
| Poor prognosis<br> | Procedure: Microwave abaltion<br>* Use microwave ablation to treat hepatocellular carcinoma<br>|
| Recurrence<br> | Procedure: Microwave abaltion<br>* Use microwave ablation to treat hepatocellular carcinoma<br>|
| Not Recurrence<br> | Procedure: Microwave abaltion<br>* Use microwave ablation to treat hepatocellular carcinoma<br>|
| Survival<br> | Procedure: Microwave abaltion<br>* Use microwave ablation to treat hepatocellular carcinoma<br>|
| Death<br> | Procedure: Microwave abaltion<br>* Use microwave ablation to treat hepatocellular carcinoma<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUC value | Utilizing area under curve to judge the accurency | through study completion, an average of 2 year | 
| Sensitivity | diagnosis sensitivity of intelligent ultrasound analysis | through study completion, an average of 2 year | 
| Specificity | diagnosis specificity of intelligent ultrasound analysis | through study completion, an average of 2 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
radiomics, prognosis